Market Access Architecture
A Blueprint for Repeatable Clinical Adoption.
Strategic Briefing|By Scott Robitaille
A structured methodology for turning scientific validation into scalable clinical revenue.
Core Thesis
Market access is not a reimbursement problem. It is an architecture problem.
The Problem Is Not Access. It Is Architecture.
Most diagnostic companies believe market access begins after regulatory clearance.
That assumption is wrong.
Clinical validation does not create access.
Coverage does not create utilization.
Access does not create adoption.
Across healthcare, innovation consistently fails to scale not because the technology does not work, but because the system required to support adoption was never designed.
Promising solutions become trapped in pilots, publications, and early enthusiasm, without ever translating into repeatable clinical use.
This is not a commercialization gap.
It is an architecture failure.
Market Access Is a System, Not a Step
Market access is often treated as a downstream function.
In reality, it is a coordinated system that connects clinical evidence, regulatory positioning, reimbursement pathway design, economic value, provider workflow, and stakeholder alignment.
When these elements are disconnected, adoption stalls.
When they are designed as a system, access becomes scalable.
Market access is not about getting paid.
It is about getting used.
The Failure of the Sequential Model
Most companies still operate with a linear commercialization model.
- Develop the product
- Generate clinical data
- Obtain regulatory clearance
- Pursue reimbursement
- Launch commercially
This model fails because each step is interdependent.
- Evidence requirements are shaped by reimbursement
- Reimbursement depends on economic value
- Economic value depends on use case definition
- Adoption depends on workflow integration
Treating these as sequential decisions creates fragmentation.
Market access must be designed upstream, not addressed downstream.
Are you designing market access before launch?
View our Commercialization Architecture frameworkThe AdvisoryDx Market Access Architecture
Market access requires a structured architecture. Not a collection of activities, but a coordinated system.
Indication and Use Case Precision
Defines where the product wins, not just where it works. Focus must be placed on clinical scenarios where decision impact and economic value are highest.
Evidence Strategy Must Align to Value
Clinical validity alone is not enough. Evidence must demonstrate economic and operational relevance.
Reimbursement Pathway Design Must Occur Early
Coverage is not discovered after launch. It is designed through coding strategy, payment alignment, and site of care economics.
Value Narrative Must Align Across Stakeholders
Payers, providers, and health systems each evaluate value differently and require distinct, aligned messaging.
Access Enablement Infrastructure Determines Adoption
Workflow integration, billing support, and provider enablement drive actual utilization.
From Coverage to Adoption
Market access is not complete when a product is reimbursed.
It is complete when it is used consistently.
Three conditions must exist.
Adoption Requirements
Coverage
The product is reimbursed and economically viable.
Confidence
Providers trust the clinical and economic value.
Continuity
The product is embedded into routine workflows.
Without these, adoption remains inconsistent.
With these, adoption becomes repeatable.
Why This Matters Now
Diagnostics innovation is accelerating.
Adoption is not.
The industry does not have a technology problem.
It has a commercialization architecture problem.
Companies that design market access early will scale.
Those that treat it as a late stage function will stall.
Final Thought
The companies that win are not those with the most advanced technology.
They are the ones that design how that technology gets used.
Market access is not a hurdle.
It is the system that determines whether innovation reaches patients or stops at validation.
Design Access Before You Pursue It
AdvisoryDx works with diagnostic companies to architect commercialization decisions before launch and install the infrastructure required for repeatable adoption.